| Abeln Markus |
Gangliosides as potential complement glycotherapeutics - Fetal death of sialoglycan deficient embryos is independent of C5.
|
| Acker Elizabeth |
Complement inhibition facilitates lesion repair in an ex vivo model of neuromyelitis optica lesion formation
|
| Afzali Ben |
Regulation of Inflammation by local complement in COVID-19
|
| Agarwal Sarika |
Evaluation of the expanded Quidel MicroVue Complement Multiplex platform in human, cynomolgus monkey, and rhesus monkey samples
|
| Amstadt Robert |
AMD is Two Distinct Biological Diseases: Chromosome 1-directed Therapeutics for Future Clinical Trials and Treatment
|
| Annamalai Balasubramaniam |
A complement alternative pathway inhibitor delivered by gene therapy in a mouse model of RPE damage is effective only after subretinal rather than intravitreal placement.
|
| Anstadt Robert |
Elucidating the association between complement factor H-related 4 and age-related macular degeneration
|
| Arepally Gowthami |
Complement masks Fc regions on HIT immune complexes and prevents their recognition by cellular Fc receptors
|
| Atkinson Carl |
Bifunctional complement inhibitor protects against autoantibody-mediated ischemia reperfusion injury in lung transplantation
|
| Baas Frank |
The contribution of the terminal pathway to disease progression in neurological disorders
|
| Barciszewska Anna-Maria |
The epigenetic effect of Temozolomide, Valproic acid, and Dexamethasone on glioblastoma cell lines and their effect on complement system
|
| Baric Ralph |
Complement signaling mediates coronavirus-induced lung injury
|
| Baskar Sivasubramanian |
Potentiating anti-CD20 Monoclonal Antibody Therapy by Targeting Complement C3 Activation Fragments Covalently Deposited on Lymphoma Cells
|
| Batista Andre |
Global C3 lowering in adult mice protects against hippocampal aging
|
| Baz Morelli Adriana |
Sialylation-dependent clearance of CR1: Pharmacokinetic and pharmacodynamic characterization
|
| Bazmorelli Adriana |
Comparative efficacy of soluble CR1 variants in a mouse model of renal ischemia-reperfusion injury
|
| Beach Callum |
Targeting C5aR1 improves radiotherapy by increasing CX3CR1+ macrophage-dependent clearance of apoptotic cells in normal tissue and improving responses in immune-excluded tumours
|
| Belter Agnieszka |
The epigenetic effect of Temozolomide, Valproic acid, and Dexamethasone on glioblastoma cell lines and their effect on complement system
|
| Bennett Jeffrey |
Complement inhibition facilitates lesion repair in an ex vivo model of neuromyelitis optica lesion formation
|
| Bevan Ryan |
Targeting novel anti-complement drugs to the brain for therapy of dementia.
|
| Bieber Katja |
The C5a/C5aR1 axis controls the early IgM to IgG switch of collagen type VII autoantibodies in experimental Pemphigoid Disease
|
| Biglarnia Alireza |
A preclinical study of a novel ex-vivo cell-coating construct protecting against ischemia/ reperfusion injury in kidney transplantation
|
| Bloemenkamp Lauri |
ARGX-117, a therapeutic antibody targeting C2, blocks complement activation in a disease model for multifocal motor neuropathy
|
| Bongoni Anjan |
Comparative efficacy of soluble CR1 variants in a mouse model of renal ischemia-reperfusion injury
|
| Borus Sina |
The C5a/C5aR1 axis controls the early IgM to IgG switch of collagen type VII autoantibodies in experimental Pemphigoid Disease
|
| Bottazzi Barbara |
The long pentraxin PTX3 modulates SARS-COV-2 immune response by interacting with Nucleocapsid protein
|
| Boudhabhay I |
Complement implication in the acute kidney injury associated with rhabdomyolysis
|
| Bourdin Antonin |
Intracellular activation and regulation of the complosome – driver of cancer progression
|
| Braaten Tonje |
Venous air embolism activates complement C3 without corresponding C5 activation and trigger thromboinflammation in pigs
|
| Brekke Ole |
Effects of complement C3, C5 and CD14 inhibitors on bacterial survival and thromboinflammation induced by two different live E.coli-strains in human whole blood
|
| Buczacki Simon |
Targeting C5aR1 improves radiotherapy by increasing CX3CR1+ macrophage-dependent clearance of apoptotic cells in normal tissue and improving responses in immune-excluded tumours
|
| Budding Kevin |
ARGX-117, a therapeutic antibody targeting C2, blocks complement activation in a disease model for multifocal motor neuropathy
|
| Cammett Tobin |
Short- and long-term blood and urine storage: implications for complement C5b-9 research and diagnostic development
|
| Cao Helen |
Sialylation-dependent clearance of CR1: Pharmacokinetic and pharmacodynamic characterization
|
| Carney Kate |
Complement biomarker analysis from a first-in-human phase I/II gene therapy trial (FOCUS) of subretinally delivered GT005, an investigational AAV2-factor I vector, in patients with geographic atrophy secondary to age-related macular degeneration
|
| Carroll Michael |
Global C3 lowering in adult mice protects against hippocampal aging
|
| Caruso Antonello |
Mathematical Model of the Alternative Pathway: a Tool to Identify Optimal Pharmacological Targets
|
| Casey Kerriann |
Targeting C5aR1 improves radiotherapy by increasing CX3CR1+ macrophage-dependent clearance of apoptotic cells in normal tissue and improving responses in immune-excluded tumours
|
| Chonat Satheesh |
Complement activation in intravascular hemolysis relies on heme-depended inactivation of factor I
|
| Christiansen Dorte |
Venous air embolism activates complement C3 without corresponding C5 activation and trigger thromboinflammation in pigs
Effects of complement C3, C5 and CD14 inhibitors on bacterial survival and thromboinflammation induced by two different live E.coli-strains in human whole blood
|
| Cines Douglas |
Complement masks Fc regions on HIT immune complexes and prevents their recognition by cellular Fc receptors
|
| Clark Richard |
Targeted colon delivery of pH-sensitive PMX205-loaded nanoparticles for the treatment of the inflammatory bowel disease.
|
| Coelho Medeiros Pedro |
Evaluation of a novel cell depletion model and the characterization of cytokine response by individual cell populations in the lepirudin human whole blood model
|
| Cordioli Mattia |
Genetic Determinants of Mannose-binding Lectin Activity Predispose to Thromboembolic Complications in Critical COVID-19
|
| Cowan Peter |
Comparative efficacy of soluble CR1 variants in a mouse model of renal ischemia-reperfusion injury
|
| Cox Thomas |
Development and testing of ‘super-functional’ Factor I based constructs for multiple disease modalities.
A phase 1 healthy subject study of CAN106, a long-acting anti-C5 mAb in clinical development for complement-mediated diseases
|
| Cui Cedric |
Targeted colon delivery of pH-sensitive PMX205-loaded nanoparticles for the treatment of the inflammatory bowel disease.
|
| Curtin Karen |
AMD is Two Distinct Biological Diseases: Chromosome 1-directed Therapeutics for Future Clinical Trials and Treatment
|
| Curtiss Darin |
Complement biomarker analysis from a first-in-human phase I/II gene therapy trial (FOCUS) of subretinally delivered GT005, an investigational AAV2-factor I vector, in patients with geographic atrophy secondary to age-related macular degeneration
|
| Cyranka Leon |
Combined inhibition of complement (C3/C5) and the Toll-like receptors co-factor CD14 in inflammation induced by Candida spp.
|
| Damavandi Darvish Mahnaz |
Targeting C5aR1 improves radiotherapy by increasing CX3CR1+ macrophage-dependent clearance of apoptotic cells in normal tissue and improving responses in immune-excluded tumours
|
| Daugan Marie |
In situ complementomics reveals intratumoral complement activation, leading to poor prognosis in renal cancer
|
| de Haard Hans |
ARGX-117, a therapeutic antibody targeting C2, blocks complement activation in a disease model for multifocal motor neuropathy
|
| de Souza Mitchell |
Sialylation-dependent clearance of CR1: Pharmacokinetic and pharmacodynamic characterization
|
| De Strooper Bart |
Targeting novel anti-complement drugs to the brain for therapy of dementia.
|
| de Zeeuw Elisabeth |
ARGX-117, a therapeutic antibody targeting C2, blocks complement activation in a disease model for multifocal motor neuropathy
|
| Denhardt-Eriksson Robin |
Mathematical Model of the Alternative Pathway: a Tool to Identify Optimal Pharmacological Targets
|
| Dewilde Maarten |
Targeting novel anti-complement drugs to the brain for therapy of dementia.
|
| Dijkxhoorn Kim |
ARGX-117, a therapeutic antibody targeting C2, blocks complement activation in a disease model for multifocal motor neuropathy
|
| Dimitrov Jordan |
Complement activation in intravascular hemolysis relies on heme-depended inactivation of factor I
|
| Dower Steven |
Sialylation-dependent clearance of CR1: Pharmacokinetic and pharmacodynamic characterization
|
| Dragon-Durey Marie-Agnès |
In situ complementomics reveals intratumoral complement activation, leading to poor prognosis in renal cancer
|
| Dreismann Anna |
Complement biomarker analysis from a first-in-human phase I/II gene therapy trial (FOCUS) of subretinally delivered GT005, an investigational AAV2-factor I vector, in patients with geographic atrophy secondary to age-related macular degeneration
|
| Dybwik Knut |
Venous air embolism activates complement C3 without corresponding C5 activation and trigger thromboinflammation in pigs
|
| Eikrem David |
Recognition of post-translational lysine modifications by the lectin pathway initiator ficolin-3
|
| Ekdahl Kristina |
A preclinical study of a novel ex-vivo cell-coating construct protecting against ischemia/ reperfusion injury in kidney transplantation
Complement activation in intravascular hemolysis relies on heme-depended inactivation of factor I
Complement-induced prothrombotic activation of platelets requires the lysis of cells
|
| Elvington Michelle |
Short- and long-term blood and urine storage: implications for complement C5b-9 research and diagnostic development
|
| Eriksson Oskar |
Genetic Determinants of Mannose-binding Lectin Activity Predispose to Thromboembolic Complications in Critical COVID-19
Recognition of post-translational lysine modifications by the lectin pathway initiator ficolin-3
|
| Erkisson Oskar |
Complement-induced prothrombotic activation of platelets requires the lysis of cells
|
| Espevik Terje |
Effects of complement C3, C5 and CD14 inhibitors on bacterial survival and thromboinflammation induced by two different live E.coli-strains in human whole blood
Activation of the complement system by cholesterol crystals
|
| Fageräng Beatrice |
Evaluation of a novel cell depletion model and the characterization of cytokine response by individual cell populations in the lepirudin human whole blood model
|
| Fenske Arno |
Gangliosides as potential complement glycotherapeutics - Fetal death of sialoglycan deficient embryos is independent of C5.
|
| Fisicaro Nella |
Comparative efficacy of soluble CR1 variants in a mouse model of renal ischemia-reperfusion injury
|
| Francis Jean |
Systemic C3 inhibition in a patient with CSMD1 mutation and multi-systemic inflammatory disease.
Complement biomarker analysis from a first-in-human phase I/II gene therapy trial (FOCUS) of subretinally delivered GT005, an investigational AAV2-factor I vector, in patients with geographic atrophy secondary to age-related macular degeneration
|
| Frazer-Abel Ashley |
Lest we forget: Lessons from complement reactions to oligos, anti drug antibodies and AAV gene therapy.
|
| Fremeaux-Bacchi veronique |
Targeted Panels or Exome – Which is the Right NGS Approach for complement-mediated diseases?
|
| Fridman Wolf Herman |
Intracellular activation and regulation of the complosome – driver of cancer progression
In situ complementomics reveals intratumoral complement activation, leading to poor prognosis in renal cancer
|
| Frieri Camilla |
Discovering C3-targeting therapies for paroxysmal nocturnal hemoglobinuria: achievements and pitfalls
|
| Frithiof Robert |
Genetic Determinants of Mannose-binding Lectin Activity Predispose to Thromboembolic Complications in Critical COVID-19
|
| Fure Hilde |
Venous air embolism activates complement C3 without corresponding C5 activation and trigger thromboinflammation in pigs
|
| Gaglione Erika |
Potentiating anti-CD20 Monoclonal Antibody Therapy by Targeting Complement C3 Activation Fragments Covalently Deposited on Lymphoma Cells
|
| Gandini Domenica |
ARGX-117, a therapeutic antibody targeting C2, blocks complement activation in a disease model for multifocal motor neuropathy
|
| Garcia Brandon |
Complement masks Fc regions on HIT immune complexes and prevents their recognition by cellular Fc receptors
|
| Gardenal Emanuela |
Complement biomarker analysis from a first-in-human phase I/II gene therapy trial (FOCUS) of subretinally delivered GT005, an investigational AAV2-factor I vector, in patients with geographic atrophy secondary to age-related macular degeneration
|
| Garlanda Cecilia |
The long pentraxin PTX3 modulates SARS-COV-2 immune response by interacting with Nucleocapsid protein
Recognition and inhibition of SARS-CoV-2 by humoral innate immunity pattern recognition molecules
|
| Garred Peter |
Recognition of post-translational lysine modifications by the lectin pathway initiator ficolin-3
Combined inhibition of complement (C3/C5) and the Toll-like receptors co-factor CD14 in inflammation induced by Candida spp.
Evaluation of a novel cell depletion model and the characterization of cytokine response by individual cell populations in the lepirudin human whole blood model
|
| Geisbrecht Brian |
Modified DNA aptamers as inhibitors of complement proteins and their complexes
|
| Geisler Tobias |
Platelets balance revascularization by anaphylatoxin C5a receptor-dependent release of paracrine factors
|
| Gerogianni Alexandra |
Complement activation in intravascular hemolysis relies on heme-depended inactivation of factor I
|
| Ghosh Subhajit |
Sialylation-dependent clearance of CR1: Pharmacokinetic and pharmacodynamic characterization
|
| Giaccia Amato |
Targeting C5aR1 improves radiotherapy by increasing CX3CR1+ macrophage-dependent clearance of apoptotic cells in normal tissue and improving responses in immune-excluded tumours
|
| Gilardin L |
Complement implication in the acute kidney injury associated with rhabdomyolysis
|
| Gilliam Troy |
Evaluation of the expanded Quidel MicroVue Complement Multiplex platform in human, cynomolgus monkey, and rhesus monkey samples
|
| Given Katherine |
Complement inhibition facilitates lesion repair in an ex vivo model of neuromyelitis optica lesion formation
|
| Gralinski Lisa |
Complement signaling mediates coronavirus-induced lung injury
|
| Graves Edward |
Targeting C5aR1 improves radiotherapy by increasing CX3CR1+ macrophage-dependent clearance of apoptotic cells in normal tissue and improving responses in immune-excluded tumours
|
| Grip Jonathan |
Genetic Determinants of Mannose-binding Lectin Activity Predispose to Thromboembolic Complications in Critical COVID-19
|
| Grond Joost |
Effects of complement C3, C5 and CD14 inhibitors on bacterial survival and thromboinflammation induced by two different live E.coli-strains in human whole blood
|
| Gros Piet |
Structural insights into complement protease complexes
|
| Grunenwald Anne |
Complement activation implication in Sickle Cell Disease organ injuries in patients and a mice model
Complement implication in the acute kidney injury associated with rhabdomyolysis
|
| Hack C. |
ARGX-117, a therapeutic antibody targeting C2, blocks complement activation in a disease model for multifocal motor neuropathy
|
| Hafner Susanne |
Complement-induced prothrombotic activation of platelets requires the lysis of cells
|
| Hageman Gregory |
Elucidating the association between complement factor H-related 4 and age-related macular degeneration
AMD is Two Distinct Biological Diseases: Chromosome 1-directed Therapeutics for Future Clinical Trials and Treatment
|
| Hajishengallis George |
Complement is required for microbe-driven induction of Th17 and periodontitis
|
| Halder Partho |
Sialylation-dependent clearance of CR1: Pharmacokinetic and pharmacodynamic characterization
|
| Hallam Thomas |
Development and testing of ‘super-functional’ Factor I based constructs for multiple disease modalities.
|
| Halvorsen Bente |
Activation of the complement system by cholesterol crystals
|
| Han Felicity |
Targeted colon delivery of pH-sensitive PMX205-loaded nanoparticles for the treatment of the inflammatory bowel disease.
|
| Hardy Matthew |
Sialylation-dependent clearance of CR1: Pharmacokinetic and pharmacodynamic characterization
Comparative efficacy of soluble CR1 variants in a mouse model of renal ischemia-reperfusion injury
|
| Harris Hailey |
Complement masks Fc regions on HIT immune complexes and prevents their recognition by cellular Fc receptors
Complement biomarker analysis from a first-in-human phase I/II gene therapy trial (FOCUS) of subretinally delivered GT005, an investigational AAV2-factor I vector, in patients with geographic atrophy secondary to age-related macular degeneration
|
| Hassan Hamza |
Systemic C3 inhibition in a patient with CSMD1 mutation and multi-systemic inflammatory disease.
|
| Hevey Rachel |
Design and in vitro Evaluation of Collectin-11 Antagonists for the Treatment of Ischemia-Reperfusion Injuries
|
| Ho Jennifer |
Systemic C3 inhibition in a patient with CSMD1 mutation and multi-systemic inflammatory disease.
|
| Huber-Lang Markus |
Is therapeutic complement modulation beneficial after trauma?
Targeting complement in COVID-19: where we stand and what lies ahead
Complement-induced prothrombotic activation of platelets requires the lysis of cells
|
| Hughes Jane |
Complement biomarker analysis from a first-in-human phase I/II gene therapy trial (FOCUS) of subretinally delivered GT005, an investigational AAV2-factor I vector, in patients with geographic atrophy secondary to age-related macular degeneration
|
| Hultström Michael |
Genetic Determinants of Mannose-binding Lectin Activity Predispose to Thromboembolic Complications in Critical COVID-19
|
| Ideguchi Hidetaka |
Complement is required for microbe-driven induction of Th17 and periodontitis
|
| Iyer Shyam |
Development and testing of ‘super-functional’ Factor I based constructs for multiple disease modalities.
|
| Jacob Roman |
Design and in vitro Evaluation of Collectin-11 Antagonists for the Treatment of Ischemia-Reperfusion Injuries
|
| James Hannah |
Sialylation-dependent clearance of CR1: Pharmacokinetic and pharmacodynamic characterization
|
| Jensen Marianne |
A preclinical study of a novel ex-vivo cell-coating construct protecting against ischemia/ reperfusion injury in kidney transplantation
Development and testing of ‘super-functional’ Factor I based constructs for multiple disease modalities.
|
| Jiang Yanyan |
Targeting C5aR1 improves radiotherapy by increasing CX3CR1+ macrophage-dependent clearance of apoptotic cells in normal tissue and improving responses in immune-excluded tumours
|
| Johansen Lill |
ARGX-117, a therapeutic antibody targeting C2, blocks complement activation in a disease model for multifocal motor neuropathy
|
| Jones Bryan |
A complement alternative pathway inhibitor delivered by gene therapy in a mouse model of RPE damage is effective only after subretinal rather than intravitreal placement.
|
| Kajikawa Tetsuhiro |
Complement is required for microbe-driven induction of Th17 and periodontitis
|
| Kavian-Tesslar Niloufar |
The long pentraxin PTX3 modulates SARS-COV-2 immune response by interacting with Nucleocapsid protein
|
| Kemper Claudia |
Activation of the complement system by cholesterol crystals
|
| Kenno Samyr |
The C5a/C5aR1 axis controls the early IgM to IgG switch of collagen type VII autoantibodies in experimental Pemphigoid Disease
|
| Khan Khyrul |
Global C3 lowering in adult mice protects against hippocampal aging
|
| Khandelwal Sanjay |
Complement masks Fc regions on HIT immune complexes and prevents their recognition by cellular Fc receptors
|
| Khoo Chin Meng |
A phase 1 healthy subject study of CAN106, a long-acting anti-C5 mAb in clinical development for complement-mediated diseases
|
| Kim Ryan |
Targeting C5aR1 improves radiotherapy by increasing CX3CR1+ macrophage-dependent clearance of apoptotic cells in normal tissue and improving responses in immune-excluded tumours
|
| Köhl Jörg |
The C5a/C5aR1 axis controls the early IgM to IgG switch of collagen type VII autoantibodies in experimental Pemphigoid Disease
|
| Koong Albert |
Targeting C5aR1 improves radiotherapy by increasing CX3CR1+ macrophage-dependent clearance of apoptotic cells in normal tissue and improving responses in immune-excluded tumours
|
| Kortvely Elod |
Mathematical Model of the Alternative Pathway: a Tool to Identify Optimal Pharmacological Targets
|
| Korzenik Josh |
Systemic C3 inhibition in a patient with CSMD1 mutation and multi-systemic inflammatory disease.
|
| Kuehnemuth Benjamin |
Sialylation-dependent clearance of CR1: Pharmacokinetic and pharmacodynamic characterization
|
| Kumar Vinod |
Targeted colon delivery of pH-sensitive PMX205-loaded nanoparticles for the treatment of the inflammatory bowel disease.
|
| Lambris John |
Effects of complement C3, C5 and CD14 inhibitors on bacterial survival and thromboinflammation induced by two different live E.coli-strains in human whole blood
Discovering C3-targeting therapies for paroxysmal nocturnal hemoglobinuria: achievements and pitfalls
Complement masks Fc regions on HIT immune complexes and prevents their recognition by cellular Fc receptors
Is therapeutic complement modulation beneficial after trauma?
Targeting complement in COVID-19: where we stand and what lies ahead
Taking C3 inhibition to the next level: new insights and clinical opportunities
Complement-induced prothrombotic activation of platelets requires the lysis of cells
Complement is required for microbe-driven induction of Th17 and periodontitis
|
| Landsem Anne |
Venous air embolism activates complement C3 without corresponding C5 activation and trigger thromboinflammation in pigs
Effects of complement C3, C5 and CD14 inhibitors on bacterial survival and thromboinflammation induced by two different live E.coli-strains in human whole blood
|
| Langer Harald |
The intertwined relationship between complement and platelet activation
Platelets balance revascularization by anaphylatoxin C5a receptor-dependent release of paracrine factors
|
| Langerude Logan |
Bifunctional complement inhibitor protects against autoantibody-mediated ischemia reperfusion injury in lung transplantation
|
| Lau Corinna |
Evaluation of a novel cell depletion model and the characterization of cytokine response by individual cell populations in the lepirudin human whole blood model
Effects of complement C3, C5 and CD14 inhibitors on bacterial survival and thromboinflammation induced by two different live E.coli-strains in human whole blood
|
| Lavergne Julien |
Complement activation implication in Sickle Cell Disease organ injuries in patients and a mice model
|
| Le Quynh-Thu |
Targeting C5aR1 improves radiotherapy by increasing CX3CR1+ macrophage-dependent clearance of apoptotic cells in normal tissue and improving responses in immune-excluded tumours
|
| Lee John |
Targeted colon delivery of pH-sensitive PMX205-loaded nanoparticles for the treatment of the inflammatory bowel disease.
|
| Leedham Simon |
Targeting C5aR1 improves radiotherapy by increasing CX3CR1+ macrophage-dependent clearance of apoptotic cells in normal tissue and improving responses in immune-excluded tumours
|
| Leist Sarah |
Complement signaling mediates coronavirus-induced lung injury
|
| Lemere Cynthia |
Global C3 lowering in adult mice protects against hippocampal aging
|
| Leong David |
Sialylation-dependent clearance of CR1: Pharmacokinetic and pharmacodynamic characterization
|
| Leusen Jeanette |
ARGX-117, a therapeutic antibody targeting C2, blocks complement activation in a disease model for multifocal motor neuropathy
|
| Li Changhai |
Bifunctional complement inhibitor protects against autoantibody-mediated ischemia reperfusion injury in lung transplantation
Global C3 lowering in adult mice protects against hippocampal aging
Targeted colon delivery of pH-sensitive PMX205-loaded nanoparticles for the treatment of the inflammatory bowel disease.
|
| Lind Holger |
Sialylation-dependent clearance of CR1: Pharmacokinetic and pharmacodynamic characterization
|
| Lindelöf Linnea |
Recognition of post-translational lysine modifications by the lectin pathway initiator ficolin-3
Genetic Determinants of Mannose-binding Lectin Activity Predispose to Thromboembolic Complications in Critical COVID-19
|
| Lindorfer Margaret |
Potentiating anti-CD20 Monoclonal Antibody Therapy by Targeting Complement C3 Activation Fragments Covalently Deposited on Lymphoma Cells
|
| Lipcsey Miklós |
Genetic Determinants of Mannose-binding Lectin Activity Predispose to Thromboembolic Complications in Critical COVID-19
|
| Liu Jin |
AMD is Two Distinct Biological Diseases: Chromosome 1-directed Therapeutics for Future Clinical Trials and Treatment
Targeted colon delivery of pH-sensitive PMX205-loaded nanoparticles for the treatment of the inflammatory bowel disease.
Elucidating the association between complement factor H-related 4 and age-related macular degeneration
|
| Ludviksen Judith |
Venous air embolism activates complement C3 without corresponding C5 activation and trigger thromboinflammation in pigs
Effects of complement C3, C5 and CD14 inhibitors on bacterial survival and thromboinflammation induced by two different live E.coli-strains in human whole blood
|
| Luebken Antje |
Platelets balance revascularization by anaphylatoxin C5a receptor-dependent release of paracrine factors
|
| Lupu Ludmila |
Is therapeutic complement modulation beneficial after trauma?
|
| Machacek Matthias |
Mathematical Model of the Alternative Pathway: a Tool to Identify Optimal Pharmacological Targets
|
| MacLean David |
Targeting C5aR1 improves radiotherapy by increasing CX3CR1+ macrophage-dependent clearance of apoptotic cells in normal tissue and improving responses in immune-excluded tumours
|
| Majorova Dominika |
Targeting C5aR1 improves radiotherapy by increasing CX3CR1+ macrophage-dependent clearance of apoptotic cells in normal tissue and improving responses in immune-excluded tumours
|
| Manivel Vivek |
Complement-induced prothrombotic activation of platelets requires the lysis of cells
|
| Mannes Marco |
Is therapeutic complement modulation beneficial after trauma?
Complement-induced prothrombotic activation of platelets requires the lysis of cells
|
| Mantovani Alberto |
The long pentraxin PTX3 modulates SARS-COV-2 immune response by interacting with Nucleocapsid protein
|
| Marano Luana |
Discovering C3-targeting therapies for paroxysmal nocturnal hemoglobinuria: achievements and pitfalls
|
| Marchbank Kevin |
Development and testing of ‘super-functional’ Factor I based constructs for multiple disease modalities.
|
| Maricic Tomislav |
Genetic Determinants of Mannose-binding Lectin Activity Predispose to Thromboembolic Complications in Critical COVID-19
|
| Mastellos Dimitrios |
Discovering C3-targeting therapies for paroxysmal nocturnal hemoglobinuria: achievements and pitfalls
Targeting complement in COVID-19: where we stand and what lies ahead
Complement is required for microbe-driven induction of Th17 and periodontitis
|
| Matthews Stacie |
Elucidating the association between complement factor H-related 4 and age-related macular degeneration
|
| Maughan Tim |
Targeting C5aR1 improves radiotherapy by increasing CX3CR1+ macrophage-dependent clearance of apoptotic cells in normal tissue and improving responses in immune-excluded tumours
|
| Mc Adam Karin |
Evaluation of a novel cell depletion model and the characterization of cytokine response by individual cell populations in the lepirudin human whole blood model
|
| McAdam Karin |
Complement activation in intravascular hemolysis relies on heme-depended inactivation of factor I
|
| McGuire James |
Development and testing of ‘super-functional’ Factor I based constructs for multiple disease modalities.
|
| McQuiston Alexander |
Bifunctional complement inhibitor protects against autoantibody-mediated ischemia reperfusion injury in lung transplantation
|
| McRae Jennifer |
Comparative efficacy of soluble CR1 variants in a mouse model of renal ischemia-reperfusion injury
|
| Medeiros Pedro Miguel Coelho |
Combined inhibition of complement (C3/C5) and the Toll-like receptors co-factor CD14 in inflammation induced by Candida spp.
|
| Mei Michelle |
Global C3 lowering in adult mice protects against hippocampal aging
|
| Melemenidis Stavros |
Targeting C5aR1 improves radiotherapy by increasing CX3CR1+ macrophage-dependent clearance of apoptotic cells in normal tissue and improving responses in immune-excluded tumours
|
| Mendonca Luisa |
Complement biomarker analysis from a first-in-human phase I/II gene therapy trial (FOCUS) of subretinally delivered GT005, an investigational AAV2-factor I vector, in patients with geographic atrophy secondary to age-related macular degeneration
|
| Millman Ellen |
Short- and long-term blood and urine storage: implications for complement C5b-9 research and diagnostic development
|
| Mills Daniel |
Short- and long-term blood and urine storage: implications for complement C5b-9 research and diagnostic development
|
| Mischnik Marcel |
Sialylation-dependent clearance of CR1: Pharmacokinetic and pharmacodynamic characterization
|
| Mohlin Camilla |
Complement activation in intravascular hemolysis relies on heme-depended inactivation of factor I
|
| Mollnes Tom |
Effects of complement C3, C5 and CD14 inhibitors on bacterial survival and thromboinflammation induced by two different live E.coli-strains in human whole blood
Venous air embolism activates complement C3 without corresponding C5 activation and trigger thromboinflammation in pigs
Is therapeutic complement modulation beneficial after trauma?
Combined inhibition of complement (C3/C5) and the Toll-like receptors co-factor CD14 in inflammation induced by Candida spp.
Complement activation in intravascular hemolysis relies on heme-depended inactivation of factor I
Activation of the complement system by cholesterol crystals
Evaluation of a novel cell depletion model and the characterization of cytokine response by individual cell populations in the lepirudin human whole blood model
|
| Montgomery Robert |
Clinical Xenotransplantation: Implications for Complement Inhibition
|
| Moon Eui Jung |
Targeting C5aR1 improves radiotherapy by increasing CX3CR1+ macrophage-dependent clearance of apoptotic cells in normal tissue and improving responses in immune-excluded tumours
|
| Morgan Bryan |
Targeting novel anti-complement drugs to the brain for therapy of dementia.
Targeting complement for therapy of neurodegenerative diseases.
|
| Münster-Kühnel Anja |
Gangliosides as potential complement glycotherapeutics - Fetal death of sialoglycan deficient embryos is independent of C5.
|
| Nambiar Dhanya |
Targeting C5aR1 improves radiotherapy by increasing CX3CR1+ macrophage-dependent clearance of apoptotic cells in normal tissue and improving responses in immune-excluded tumours
|
| Naskręt-Barciszewska Miroslawa |
The epigenetic effect of Temozolomide, Valproic acid, and Dexamethasone on glioblastoma cell lines and their effect on complement system
|
| Nicholson Crystal |
A complement alternative pathway inhibitor delivered by gene therapy in a mouse model of RPE damage is effective only after subretinal rather than intravitreal placement.
|
| Nielsen Erik |
Venous air embolism activates complement C3 without corresponding C5 activation and trigger thromboinflammation in pigs
|
| Niemi Mari |
Genetic Determinants of Mannose-binding Lectin Activity Predispose to Thromboembolic Complications in Critical COVID-19
|
| Nilsen Bent |
Venous air embolism activates complement C3 without corresponding C5 activation and trigger thromboinflammation in pigs
|
| Nilsson Bo |
A preclinical study of a novel ex-vivo cell-coating construct protecting against ischemia/ reperfusion injury in kidney transplantation
Recognition of post-translational lysine modifications by the lectin pathway initiator ficolin-3
Targeting complement in COVID-19: where we stand and what lies ahead
Evaluation of a novel cell depletion model and the characterization of cytokine response by individual cell populations in the lepirudin human whole blood model
Complement activation in intravascular hemolysis relies on heme-depended inactivation of factor I
Complement-induced prothrombotic activation of platelets requires the lysis of cells
Genetic Determinants of Mannose-binding Lectin Activity Predispose to Thromboembolic Complications in Critical COVID-19
|
| Nilsson Ekdahl Kristina |
Recognition of post-translational lysine modifications by the lectin pathway initiator ficolin-3
Genetic Determinants of Mannose-binding Lectin Activity Predispose to Thromboembolic Complications in Critical COVID-19
|
| Niyonzima Nathalie |
Activation of the complement system by cholesterol crystals
|
| Nkambule Lindo |
Genetic Determinants of Mannose-binding Lectin Activity Predispose to Thromboembolic Complications in Critical COVID-19
|
| Nording Henry |
Platelets balance revascularization by anaphylatoxin C5a receptor-dependent release of paracrine factors
|
| Obert Elisabeth |
A complement alternative pathway inhibitor delivered by gene therapy in a mouse model of RPE damage is effective only after subretinal rather than intravitreal placement.
|
| Olcina Monica |
Targeting C5aR1 improves radiotherapy by increasing CX3CR1+ macrophage-dependent clearance of apoptotic cells in normal tissue and improving responses in immune-excluded tumours
|
| Ow Saw Yen |
Sialylation-dependent clearance of CR1: Pharmacokinetic and pharmacodynamic characterization
|
| Owczarek Catherine |
Sialylation-dependent clearance of CR1: Pharmacokinetic and pharmacodynamic characterization
|
| Pagani Isabel |
The long pentraxin PTX3 modulates SARS-COV-2 immune response by interacting with Nucleocapsid protein
|
| Pappas Chris |
AMD is Two Distinct Biological Diseases: Chromosome 1-directed Therapeutics for Future Clinical Trials and Treatment
Elucidating the association between complement factor H-related 4 and age-related macular degeneration
|
| Parsons Nathaniel |
A complement alternative pathway inhibitor delivered by gene therapy in a mouse model of RPE damage is effective only after subretinal rather than intravitreal placement.
|
| Patel Kunal |
Bifunctional complement inhibitor protects against autoantibody-mediated ischemia reperfusion injury in lung transplantation
|
| Pearse Martin |
Comparative efficacy of soluble CR1 variants in a mouse model of renal ischemia-reperfusion injury
|
| Pechtl Veronika |
Complement-induced prothrombotic activation of platelets requires the lysis of cells
|
| Peffault de Latour Regis |
Discovering C3-targeting therapies for paroxysmal nocturnal hemoglobinuria: achievements and pitfalls
|
| Pekle Eva |
Complement biomarker analysis from a first-in-human phase I/II gene therapy trial (FOCUS) of subretinally delivered GT005, an investigational AAV2-factor I vector, in patients with geographic atrophy secondary to age-related macular degeneration
|
| Peliconi Julie |
Complement activation implication in Sickle Cell Disease organ injuries in patients and a mice model
|
| Peng Haiyong |
Potentiating anti-CD20 Monoclonal Antibody Therapy by Targeting Complement C3 Activation Fragments Covalently Deposited on Lymphoma Cells
|
| Petitprez Florent |
Complement implication in the acute kidney injury associated with rhabdomyolysis
|
| Pettersen Kristin |
Venous air embolism activates complement C3 without corresponding C5 activation and trigger thromboinflammation in pigs
|
| Pigazzini Sara |
Genetic Determinants of Mannose-binding Lectin Activity Predispose to Thromboembolic Complications in Critical COVID-19
|
| Pio Ruben |
Complement-related therapies to treat cancer: where to target?
|
| Poillerat V |
Complement activation implication in Sickle Cell Disease organ injuries in patients and a mice model
Complement implication in the acute kidney injury associated with rhabdomyolysis
Complement activation in intravascular hemolysis relies on heme-depended inactivation of factor I
|
| Powers Glenn |
Sialylation-dependent clearance of CR1: Pharmacokinetic and pharmacodynamic characterization
|
| Presumey Jessy |
Global C3 lowering in adult mice protects against hippocampal aging
|
| Qamar Ali |
Measuring C5a with functional bioassay
|
| Rabbani Said |
Design and in vitro Evaluation of Collectin-11 Antagonists for the Treatment of Ischemia-Reperfusion Injuries
|
| Rader Christoph |
Potentiating anti-CD20 Monoclonal Antibody Therapy by Targeting Complement C3 Activation Fragments Covalently Deposited on Lymphoma Cells
|
| Rao Deepak |
Systemic C3 inhibition in a patient with CSMD1 mutation and multi-systemic inflammatory disease.
|
| Rauova Lubica |
Complement masks Fc regions on HIT immune complexes and prevents their recognition by cellular Fc receptors
|
| Revel Margot |
Intracellular activation and regulation of the complosome – driver of cancer progression
Complement activation implication in Sickle Cell Disease organ injuries in patients and a mice model
In situ complementomics reveals intratumoral complement activation, leading to poor prognosis in renal cancer
Complement implication in the acute kidney injury associated with rhabdomyolysis
|
| Richards Burt |
AMD is Two Distinct Biological Diseases: Chromosome 1-directed Therapeutics for Future Clinical Trials and Treatment
Elucidating the association between complement factor H-related 4 and age-related macular degeneration
|
| Ricklin Daniel |
Design and in vitro Evaluation of Collectin-11 Antagonists for the Treatment of Ischemia-Reperfusion Injuries
|
| Risitano Antonio |
Targeting complement in COVID-19: where we stand and what lies ahead
Discovering C3-targeting therapies for paroxysmal nocturnal hemoglobinuria: achievements and pitfalls
|
| Ritis Konstantinos |
Targeting complement in COVID-19: where we stand and what lies ahead
|
| Robe-Rybkine Tania |
Intracellular activation and regulation of the complosome – driver of cancer progression
Complement implication in the acute kidney injury associated with rhabdomyolysis
|
| Rohlik Denise |
Fragment-based drug design in the development of novel inhibitors against the initiating protease, C1r, of the classical pathway of complement
|
| Rohrer Bärbel |
A complement alternative pathway inhibitor delivered by gene therapy in a mouse model of RPE damage is effective only after subretinal rather than intravitreal placement.
|
| Rooijackers Olav |
Genetic Determinants of Mannose-binding Lectin Activity Predispose to Thromboembolic Complications in Critical COVID-19
|
| Rosbjerg Anne |
Combined inhibition of complement (C3/C5) and the Toll-like receptors co-factor CD14 in inflammation induced by Candida spp.
|
| Rossato Paolo |
Sialylation-dependent clearance of CR1: Pharmacokinetic and pharmacodynamic characterization
|
| Roumenina Lubka |
Intracellular activation and regulation of the complosome – driver of cancer progression
Complement activation implication in Sickle Cell Disease organ injuries in patients and a mice model
In situ complementomics reveals intratumoral complement activation, leading to poor prognosis in renal cancer
Complement implication in the acute kidney injury associated with rhabdomyolysis
Complement activation in intravascular hemolysis relies on heme-depended inactivation of factor I
Complementome as a driver of (tumor) cell fate
|
| Rowe Tony |
Sialylation-dependent clearance of CR1: Pharmacokinetic and pharmacodynamic characterization
Comparative efficacy of soluble CR1 variants in a mouse model of renal ischemia-reperfusion injury
|
| Sacks S |
Complement implication in the acute kidney injury associated with rhabdomyolysis
|
| Salant David |
Systemic C3 inhibition in a patient with CSMD1 mutation and multi-systemic inflammatory disease.
|
| Salvaris Evelyn |
Comparative efficacy of soluble CR1 variants in a mouse model of renal ischemia-reperfusion injury
|
| Sandholm Kerstin |
Complement activation in intravascular hemolysis relies on heme-depended inactivation of factor I
|
| Sautes-Fridman Catherine |
Intracellular activation and regulation of the complosome – driver of cancer progression
In situ complementomics reveals intratumoral complement activation, leading to poor prognosis in renal cancer
|
| Scavello Francesco |
The long pentraxin PTX3 modulates SARS-COV-2 immune response by interacting with Nucleocapsid protein
|
| Schjalm Camilla |
Combined inhibition of complement (C3/C5) and the Toll-like receptors co-factor CD14 in inflammation induced by Candida spp.
Evaluation of a novel cell depletion model and the characterization of cytokine response by individual cell populations in the lepirudin human whole blood model
|
| Schmidt Martin |
Short- and long-term blood and urine storage: implications for complement C5b-9 research and diagnostic development
Complement-induced prothrombotic activation of platelets requires the lysis of cells
|
| Schroeder Maren |
Global C3 lowering in adult mice protects against hippocampal aging
|
| Schwenkert Dr. Michael |
Measuring C5a with functional bioassay
|
| Seager Nathan |
AMD is Two Distinct Biological Diseases: Chromosome 1-directed Therapeutics for Future Clinical Trials and Treatment
|
| Sexton Patrick |
Evaluation of the expanded Quidel MicroVue Complement Multiplex platform in human, cynomolgus monkey, and rhesus monkey samples
|
| Shkilnyk Oksana |
Short- and long-term blood and urine storage: implications for complement C5b-9 research and diagnostic development
|
| Sidi Dieudonne |
Short- and long-term blood and urine storage: implications for complement C5b-9 research and diagnostic development
|
| Skendros Panagiotis |
Targeting complement in COVID-19: where we stand and what lies ahead
|
| Sloan John |
Systemic C3 inhibition in a patient with CSMD1 mutation and multi-systemic inflammatory disease.
|
| Smiesko Martin |
Design and in vitro Evaluation of Collectin-11 Antagonists for the Treatment of Ischemia-Reperfusion Injuries
|
| Song Charlene |
A phase 1 healthy subject study of CAN106, a long-acting anti-C5 mAb in clinical development for complement-mediated diseases
|
| Storm Benjamin |
Venous air embolism activates complement C3 without corresponding C5 activation and trigger thromboinflammation in pigs
|
| Stravalaci Matteo |
The long pentraxin PTX3 modulates SARS-COV-2 immune response by interacting with Nucleocapsid protein
|
| Stucki Manuel |
Targeting C5aR1 improves radiotherapy by increasing CX3CR1+ macrophage-dependent clearance of apoptotic cells in normal tissue and improving responses in immune-excluded tumours
|
| Tan Xiahui |
Sialylation-dependent clearance of CR1: Pharmacokinetic and pharmacodynamic characterization
|
| Taylor Ronald |
Potentiating anti-CD20 Monoclonal Antibody Therapy by Targeting Complement C3 Activation Fragments Covalently Deposited on Lymphoma Cells
|
| Teramura Yuji |
A preclinical study of a novel ex-vivo cell-coating construct protecting against ischemia/ reperfusion injury in kidney transplantation
|
| Thomas Eke Helena |
Development and testing of ‘super-functional’ Factor I based constructs for multiple disease modalities.
|
| Tiede Andreas |
Gangliosides as potential complement glycotherapeutics - Fetal death of sialoglycan deficient embryos is independent of C5.
|
| Tomasetig Vesna |
Sialylation-dependent clearance of CR1: Pharmacokinetic and pharmacodynamic characterization
|
| Tomlinson Stephen |
Bifunctional complement inhibitor protects against autoantibody-mediated ischemia reperfusion injury in lung transplantation
|
| Tu Zhenxiao |
Bifunctional complement inhibitor protects against autoantibody-mediated ischemia reperfusion injury in lung transplantation
|
| Van de Steen Olivier |
ARGX-117, a therapeutic antibody targeting C2, blocks complement activation in a disease model for multifocal motor neuropathy
|
| Van de Walle Inge |
ARGX-117, a therapeutic antibody targeting C2, blocks complement activation in a disease model for multifocal motor neuropathy
|
| van der Pol W. |
ARGX-117, a therapeutic antibody targeting C2, blocks complement activation in a disease model for multifocal motor neuropathy
|
| Varsani Sonal |
Complement biomarker analysis from a first-in-human phase I/II gene therapy trial (FOCUS) of subretinally delivered GT005, an investigational AAV2-factor I vector, in patients with geographic atrophy secondary to age-related macular degeneration
|
| Vicenzi Elisa |
The long pentraxin PTX3 modulates SARS-COV-2 immune response by interacting with Nucleocapsid protein
|
| Vikstrom Ingela |
Comparative efficacy of soluble CR1 variants in a mouse model of renal ischemia-reperfusion injury
|
| Voilin Elodie |
Complement activation implication in Sickle Cell Disease organ injuries in patients and a mice model
Complement implication in the acute kidney injury associated with rhabdomyolysis
|
| Vollmer Jannik |
Mathematical Model of the Alternative Pathway: a Tool to Identify Optimal Pharmacological Targets
|
| Waheed Nadia |
Complement biomarker analysis from a first-in-human phase I/II gene therapy trial (FOCUS) of subretinally delivered GT005, an investigational AAV2-factor I vector, in patients with geographic atrophy secondary to age-related macular degeneration
|
| Wang Hui |
Complement is required for microbe-driven induction of Th17 and periodontitis
|
| Wedekind Henri |
Gangliosides as potential complement glycotherapeutics - Fetal death of sialoglycan deficient embryos is independent of C5.
|
| Weinhold Birgit |
Gangliosides as potential complement glycotherapeutics - Fetal death of sialoglycan deficient embryos is independent of C5.
|
| West Ande |
Complement signaling mediates coronavirus-induced lung injury
|
| Whittaker Andrew |
Targeted colon delivery of pH-sensitive PMX205-loaded nanoparticles for the treatment of the inflammatory bowel disease.
|
| Wiestner Adrian |
Potentiating anti-CD20 Monoclonal Antibody Therapy by Targeting Complement C3 Activation Fragments Covalently Deposited on Lymphoma Cells
|
| Williams Brandi |
AMD is Two Distinct Biological Diseases: Chromosome 1-directed Therapeutics for Future Clinical Trials and Treatment
|
| Wohlgemuth Lisa |
Is therapeutic complement modulation beneficial after trauma?
|
| Woodruff Trent |
Targeted colon delivery of pH-sensitive PMX205-loaded nanoparticles for the treatment of the inflammatory bowel disease.
Targeting C5aR1 improves radiotherapy by increasing CX3CR1+ macrophage-dependent clearance of apoptotic cells in normal tissue and improving responses in immune-excluded tumours
Effects of complement C3, C5 and CD14 inhibitors on bacterial survival and thromboinflammation induced by two different live E.coli-strains in human whole blood
|
| Wu Judith |
A phase 1 healthy subject study of CAN106, a long-acting anti-C5 mAb in clinical development for complement-mediated diseases
|
| Würzner Reinhard |
Combined inhibition of complement (C3/C5) and the Toll-like receptors co-factor CD14 in inflammation induced by Candida spp.
|
| Wymann Sandra |
Comparative efficacy of soluble CR1 variants in a mouse model of renal ischemia-reperfusion injury
Sialylation-dependent clearance of CR1: Pharmacokinetic and pharmacodynamic characterization
|
| Yalcin Esra |
Global C3 lowering in adult mice protects against hippocampal aging
|
| Yancopoulou Despina |
Discovering C3-targeting therapies for paroxysmal nocturnal hemoglobinuria: achievements and pitfalls
Targeting complement in COVID-19: where we stand and what lies ahead
|
| Zarantonello Alessandra |
Intracellular activation and regulation of the complosome – driver of cancer progression
|
| Zeberg Hugo |
Genetic Determinants of Mannose-binding Lectin Activity Predispose to Thromboembolic Complications in Critical COVID-19
|
| Zelek Wioleta |
Targeting novel anti-complement drugs to the brain for therapy of dementia.
|
| Zhong Hang |
Role of pentraxin 3 and interaction with complement in immune defence against malaria
|
| Zong Hang |
The long pentraxin PTX3 modulates SARS-COV-2 immune response by interacting with Nucleocapsid protein
|
| Zouache Moussa |
AMD is Two Distinct Biological Diseases: Chromosome 1-directed Therapeutics for Future Clinical Trials and Treatment
Elucidating the association between complement factor H-related 4 and age-related macular degeneration
|
